FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells

TOSHIYA TAKAMURA¹², MANO HORINAKA¹, SHUSUKE YASUDA¹, SEIJIRO TORIYAMA¹², YUICHI AONO¹, YOSHIHIRO SOWA¹, TSUNEHARU MIKI²³, OSAMU UKIMURA² and TOSHIYUKI SAKAI¹

Departments of ¹Molecular-Targeting Cancer Prevention and ²Urology, Kyoto Prefectural University of Medicine, Kyoto; ³Department of Urology, Saiseikai Shiga Hospital, Shiga, Japan

Received June 7, 2017; Accepted November 6, 2017

DOI: 10.3892/or.2017.6127

Abstract. In advanced bladder cancer, cisplatin-based chemotherapy has been the standard treatment for many years, but there are many problems in terms of side-effects. Recently, a number of clinical trials using molecular-targeted agents have been conducted, and new therapies are expected that could replace conventional cytotoxic chemotherapy. We herein report that concurrent treatment with fibroblast growth factor receptor (FGFR) inhibitor BGJ398 and the novel histone deacetylase (HDAC) inhibitor OBP-801/YM753/spiruchostatin A synergistically inhibited cell growth and markedly induced apoptosis in high-grade bladder cancer cells. This combination activated caspase-3, -8 and -9, and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the combined treatment. The combination upregulated the expression of Bim, one of the pro-apoptotic molecules. In the present study, Bim siRNA efficiently reduced apoptosis induced by the co-treatment of BGJ398 and OBP-801. Therefore, the apoptosis induced by the combination was shown to be at least partially dependent on Bim. Taken together, these results suggest that the combination of BGJ398 and OBP-801 is a novel high potential therapeutic strategy for muscle-invasive bladder cancer.

Introduction

Bladder cancer is one of the most common cancers in the world, with an estimated 174,000 deaths in 2013 (1). For patients with locally advanced or metastatic bladder cancer, the standard chemotherapy is cisplatin-based combination chemotherapy. However, the 5-year survival rate in patients with stage IV bladder cancer after treatment is only around 15% (2). Considering the limited response rate of the regimens and the toxicity (3), novel therapeutic agents to replace conventional cytotoxic chemotherapy are needed.

It has been reported that genetic abnormality of various genes is observed in patients with bladder cancer. Recently, it has become clear that the signaling pathways of fibroblast growth factor receptors (FGFRs), particularly the FGFR3 (4) and FGFR1 (5) pathways, are altered in bladder cancers. FGFRs (FGFR1-FGFR4) play a key role in the regulation of proliferation, angiogenesis and apoptosis (6). Active mutations and/or overexpression of FGFR3 are common genetic alterations in non-invasive bladder cancer, but occur at a low frequency in high-grade invasive bladder cancer (8). FGFR1 is not mutated in bladder cancer, but overexpression is frequent in bladder cancer cell lines regardless of tumor grade and stage (5). In addition, it has been reported that FGFR1 expression is an adverse prognostic risk factor in muscle invasive bladder cancer after radical cystectomy (9). Recently, a number of clinical trials of BGJ398, a selective pan FGFR inhibitor, have progressed in patients with various types of cancers. In a phase 1 clinical trial using BGJ398 in patients with solid tumors carrying FGFR genetic alternations, antitumor activity was demonstrated in patients with FGFR3-mutant bladder cancer (10). Furthermore, a study of BGJ398 in non-muscle-invasive urothelial carcinoma of the bladder is currently recruiting participants. FGFR inhibitor BGJ398 is expected to be a more effective therapeutic agent for patients with bladder cancer. However, it has been reported that BGJ398 did not suppress primary tumors, but did inhibit the development of circulating tumor cells and metastasis in vivo (11).
Histone deacetylase (HDAC) inhibitors are also predicted for the treatment of various cancers including bladder cancer. It has been reported that HDAC inhibitors inhibit cell growth and induce cell death in bladder cancer cells (12). Furthermore, several studies have reported that HDAC inhibitors synergize with chemotherapeutic agents (13-15). Currently, a phase 2 clinical trial of an HDAC inhibitor for patients with bladder cancer is ongoing. OBP-801/YM753/spiruchostatin A was identified as a novel HDAC inhibitor by using a p21 promoter-reporter assay, which showed the most potent HDAC-inhibitory activity as compared to other HDAC inhibitors (16).

We showed for the first time that a combined treatment of FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibited cell growth, and induced apoptosis in human bladder cancer cells. Taken together, we suggest that the combination is a promising novel therapeutic approach to treat muscle-invasive bladder cancer.

Materials and methods

**Cell culture.** Human bladder cancer UMC-UC-3 and T24 cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cell cultures were incubated at 37˚C in a humidified atmosphere of 5% CO₂.

**Reagents.** BGJ398 was purchased from Selleck Chemicals (Houston, TX, USA). OBP-801 was supplied by Oncolyt Cell viability assay. The number of viable cells was determined by the percentage of hypodiploid DNA (sub-G1).

**Results**

**Cell viability assay.** The number of viable cells was determined using the Cell Counting Kit-8 (CCK-8) assay according to the manufacturer's instructions (Dojindo Laboratories, Kumamoto, Japan). After the incubation of cells (3x10³/well) in 96-well plates for 72 h with the indicated concentrations of BGJ398 or OBP-801, the kit reagent was added to the medium, and the plates were incubated for a further 4 h. The absorbance of samples (450 nm) was determined using a scanning multiwell spectrophotometer (DS Pharma Biomedical, Co., Ltd., Osaka, Japan).

**Combination index.** Combination index (CI) values were analyzed using CalcuSyn software (Biosoft, Great Shelford, UK). CI <1 indicates synergism greater than the expected additive effect.

**Detection of apoptosis.** After the incubation of cells (2x10³/well) in 6-well plates for 72 h with the agents, the cells were harvested. After washing with phosphate-buffered saline (PBS), the cells were treated with PBS containing 0.1% Triton X-100 and the nuclei were stained with propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA). The DNA content was measured using a FACS Calibur (Becton-Dickinson, Franklin Lakes, NJ, USA). CellQuest software (Becton-Dickinson) was used to analyze the data. DNA fragmentation was quantified by the percentage of hypodiploid DNA (sub-G1).

**Western blotting.** Western blot analysis was carried out as previously described (17). The following antibodies were purchased from the indicated sources: rabbit monoclonal antibodies for anti-Bim (ab32158) (Abcam, Cambridge, UK), anti-Bcl-xL (#2762), and anti-PARP (#9542) (Cell Signaling Technology, Beverly, MA, USA); rabbit polyclonal antibodies for anti-survivin (AF886) (R&D Systems), anti-DR5 (#8074) (Cell Signaling Technology), anti-DR4 (1139) (ProSci, Inc., Poway, CA, USA), anti-caspase-3 (#9665), anti-histone H4 (#2935), anti-acetyl-histone H4 (#9672), anti-Bid (#2002), anti-ERK1/2 (#9102), anti-Shp2 (#3752), anti-phospho ERK1/2 (#9101), anti-phospho FRS2-α (#3861), anti-phospho Shp2 (#3751) (Cell Signaling Technology), anti-FRS2-α (SC17841) (Santa Cruz Biotechnology, Dallas, TX, USA); mouse monoclonal antibodies for anti-caspase-8-M032-3 and anti-caspase-9-M054-3 (MBL, Nagoya, Japan), anti-FLIP (ACX-804-961-0100) (Enzo Life Sciences, Farmingdale, NY, USA), and anti-GAPDH (5G4) (HyTest, Ltd., Turku, Finland) were used as primary antibodies. An anti-rabbit IgG-HRP-conjugated antibody (NA934) (GE Healthcare Life Sciences, Little Chalfont, UK) and an anti-mouse IgG-HRP-conjugated antibody (NA933) (GE Healthcare Life Sciences) were used as the secondary antibodies. The signal was detected using the Chemilumi-One chemiluminescent kit (Nacalai Tesque, Inc., Kyoto, Japan) or chemiluminescent HRP substrate (Millipore, Billerica, MA, USA).

**Small interfering RNA transfection.** The Bim siRNA and the negative control siRNA were purchased from Sigma-Aldrich. The Bim siRNA (ACUUACACAGAAGGUUGC) was used for the transfection. At the same time as the transfection, UM-UC-3 and T24 cells (2x10³/well) were seeded in 6-well plates without antibiotics. The Bim siRNA (5 nM for UM-UC-3 cells or 10 nM for T24 cells) was transfected into cells using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Twenty-four hours after the transfection, the cells were treated with agents for 48 h and then harvested.

**Statistical analysis.** Data are expressed as the means ± SD of three determinations. Statistical analysis was performed using Student's t-test. Samples were considered significantly different at P<0.05.

**Results**

**Combined treatment with BGJ398 and OBP-801 synergistically inhibits cell growth in human bladder cancer cells.** To examine the anti-growth effects of BGJ398 or OBP-801 alone against human bladder cancer cells, we first assessed the viable cell number at 72 h after treatment with the indicated concentrations of the agents. Each agent suppressed the cell growth of UM-UC-3 and T24 cells in a dose-dependent manner (Fig. 1A). Notably, co-treatment with BGJ398 and OBP-801 markedly inhibited cell growth, compared with the single treatment of each agent in both cell lines (Fig. 1B). Moreover, the combination index (CI) values for BGJ398 and OBP-801 were <1.0, indicating a synergistic effect on the inhibition of cell growth (Table I).

We next examined the effects of the combined treatment of FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801...
on the FGFR signaling pathways and HDAC-inhibitory activity. OBP-801 alone and the combination increased the acetylation of histone H4 in both UM-UC-3 and T24 cells (Fig. 2A). BGJ398 alone and the combination inhibited the phosphorylation of FGFR substrate 2 (FRS2), which is a docking protein linking FGFRs, in UM-UC-3 cells. Furthermore, BGJ398 also inhibited the phosphorylation of ERK in UM-UC-3 cells (Fig. 2B). On the other hand, BGJ398 slightly inhibited phosphorylation of FRS2, and the co-treatment of OBP-801 and BGJ398 more clearly inhibited it in T24 cells. However, the treatment of BGJ398 alone and the combination did not inhibit the phosphorylation of ERK in T24 cells (Fig. 2B). Therefore, we next examined the effect of the combination on the phosphorylation of protein tyrosine phosphatase Shp2. Shp2 is a critical downstream mediator of FGFR-FRS2 signaling. As shown in Fig. 2B, the combined treatment inhibited the phosphorylation of Shp2 in T24 cells.

Combined treatment with BGJ398 and OBP-801 induces caspase-dependent apoptosis in human bladder cancer cells. To clarify the mechanisms of the synergistic inhibitory effects on cell growth of bladder cancer cells by the combined treatment with BGJ398 and OBP-801, we next investigated the effect of the combination on apoptosis by measuring the sub-G1 populations, using flow cytometry after treatment for 72 h. The co-treatment with BGJ398 and OBP-801 more markedly induced apoptosis than that of each agent alone in the UM-UC-3 and T24 cells (Fig. 3). To examine whether the apoptosis induced by the combination of the agents is caspase-dependent,
we analyzed the effect of a caspase inhibitor. The pan-caspase inhibitor zVAD-fmk effectively blocked apoptosis induced by the co-treatment with BGJ398 and OBP-801 (Fig. 3). These results suggest that the combination of BGJ398 and OBP-801 synergistically induces caspase-dependent apoptosis in human bladder cancer cells.

Figure 3. Combination treatment with BGJ398 and OBP-801 induces caspase-dependent apoptosis in human bladder cancer cells. (A) UM-UC-3 cells were treated with 4 µM BGJ398 and/or 6 nM OBP-801 with or without the pan-caspase inhibitor zVAD-fmk (20 µM) for 72 h. The apoptotic cell population was analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; **P<0.01. (B) T24 cells were treated with 2 µM BGJ398 and/or 8 nM OBP-801 with or without the pan-caspase inhibitor zVAD-fmk (20 µM) for 72 h. The apoptotic cell population was analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; **P<0.01.

Figure 4. Combined treatment with BGJ398 and OBP-801 induces caspase-dependent apoptosis in human bladder cancer cells through both intrinsic and extrinsic pathways. Western blotting of caspase-3, -8, -9, PARP, Bim, survivin, Bid, Bcl-xL, DR5, DR4 and FLIP, in UM-UC-3 and T24 cells. UM-UC-3 cells were treated with 4 µM BGJ398 and/or 6 nM OBP-801 for 48 h. T24 cells were treated with 2 µM BGJ398 and/or 8 nM OBP-801 for 48 h. GAPDH served as a loading control in all blots.
Combined treatment with BGJ398 and OBP-801 causes apoptosis via intrinsic and extrinsic pathways in human bladder cancer cells. We examined the expression of apoptosis-related proteins in the combined treatment. As shown in Fig. 4, the concurrent treatment induced the cleavage of caspase-8, caspase-9, caspase-3 and PARP. The co-treatment increased the expression of pro-apoptotic protein Bim, and reduced the expression of anti-apoptotic proteins, survivin and FLIPL, in uM-uC-3 and T24 cells (Fig. 4). The expression of DR5, one of the pro-apoptotic proteins, was upregulated by co-treatment in uM-uC-3 cells, but not in T24 cells. These results suggest that the combined treatment with BGJ398 and OBP-801 induced apoptosis through the activation of both intrinsic and extrinsic pathways in human bladder cancer cells.

Bim contributes to apoptosis by the combined treatment in bladder cancer cells. The combined treatment upregulated the expression of Bim in the uM-uC-3 and T24 cells (Fig. 4). We examined whether Bim contributed to the induction of apoptosis by co-treatment with BGJ398 and OBP-801. The effects of the Bim knockdown were confirmed by western blotting (Fig. 5). Bim siRNA significantly suppressed apoptosis induced by the combination compared with the control (Fig. 5). These results suggest that the combined treatment with BGJ398 and OBP-801 caused apoptosis at least partially through the upregulation of Bim in bladder cancer cells.

Discussion

In the present study, we showed for the first time the synergistic effect of the combined treatment with FGFR inhibitor BGJ398 and the novel HDAC inhibitor OBP-801 on cell growth arrest and apoptosis against high grade bladder cancer cells. Furthermore, the apoptosis was associated with the upregulation of Bim and DR5, and downregulation of survivin and FLIP by the combined treatment as the molecular mechanisms. In these apoptosis-related proteins, we showed that Bim knockdown significantly inhibited apoptosis induced by the combination (Fig. 5). The results suggest that the combined treatment causes apoptosis at least partially through the upregulation of Bim in bladder cancer cells.

Bim is a BH3-only pro-apoptotic member of the Bcl-2 family (18), and its expression is regulated by ERK1/2 and PI3K/AKT pathways (19). The activation of the ERK1/2 pathway induces the phosphorylation of Bim and promotes proteasome-dependent degradation of phosphorylated Bim (20). In the present study, OBP-801 slightly inhibited the phosphorylation of ERK in uM-uC-3 cells (Fig. 2B). On the other hand, the effect of BGJ398 was different in the uM-uC-3 and T24 cells. BGJ398 clearly inhibited the phosphorylation of ERK in uM-uC-3 cells (Fig. 2B). These results suggest that the expression of Bim was upregulated by the combination in ERK1/2-dependent pathways in uM-uC-3 cells.

In the present study, BGJ398 alone and co-treatment with OBP-801 inhibited the phosphorylation of FRS2 in T24 cells (Fig. 2B). On the other hand, the phosphorylation of ERK was not suppressed by these treatments in T24 cells (Fig. 2B). Therefore, we next examined whether the combination regulated Shp2 downstream of FGFR-FRS2 signaling independent of ERK. Shp2, a non-receptor phosphotyrosine phosphatase, promotes tumor progression in various cancer types (22). Furthermore, previous studies reported that Shp2 is a key regulator of cell growth and survival.
downregulator of Bim through ERK1/2 activation (23,24). Notably, in this study, the combination inhibited phosphorylation of Shp2 but not the phosphorylation of ERK in T24 cells. These data showed that Bim was upregulated by Shp2 independent of ERK in T24 cells treated by the combination, suggesting the existence of an unknown pathway between Shp2 and Bim independent of ERK.

Moreover, the expression of DR5 was upregulated by the combination in UM-UC-3 cells (Fig. 4). We previously reported that OBP-801 and celecoxib synergistically induced apoptosis via the DR5-dependent pathway, and that Bim partially acts as one of the key molecules downstream of DR5 in bladder cancer cells (17). Therefore, the DR5-dependent pathway may be partially involved in the caspase-dependent apoptosis by the combination of BGJ398 and OBP-801 in UM-UC-3 cells.

In conclusion, this is the first report showing the synergistic effect of the combination of an FGFR inhibitor and an HDAC inhibitor against human bladder cancer cells. We suggest that the combined treatment is a promising novel therapeutic approach to treat muscle-invasive bladder cancer.

Acknowledgements

The present study was supported by the Research Funding of Kyoto Prefectural University of Medicine.

References


